IBIMA

Biomedical Research Servicesibima.eu

IBIMA is a public non-profit biomedical research institute in Málaga, Spain, accredited by ISCIII, conducting translational research across eight disease areas and nanomedicine, funded by public grants and pharmaceutical clinical trial partnerships.

Company typePrivate
Founded2010
HeadquartersMálaga, Spain
Headcount51–100
GTM typeB2B
OfferingServices

What IBIMA does

IBIMA (Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina, operating as IBIMA Plataforma BIONAND) is a public, non-profit biomedical research institute headquartered at Málaga Techpark in Andalusia, Spain. Founded in July 2010 through an agreement between the Junta de Andalucía's health department and the University of Málaga, and accredited as a Health Research Institute by Spain's Instituto de Salud Carlos III on January 15, 2015, the institute operates as a multidisciplinary translational research center combining university and clinical-hospital researchers across eight areas: cardiovascular/obesity/diabetes, onco-hematology, neurosciences, autoimmune/allergic diseases, rare diseases (IBIMA-Rare), health technology and innovation (IBIMATech), nanodiagnostics, and advanced nanosystems therapies.

Its core technology infrastructure centers on the BIONAND nanomedicine platform and the Nanoimaging Unit, which holds Singular Scientific and Technological Infrastructure (ICTS) accreditation from the Spanish Ministry of Science and Innovation as an independent node of the NANBIOSIS network. Supporting platforms include a Biobank, genomics, proteomics, metabolomics, bioinformatics, cell culture, histology, and GMP-certified cellular manufacturing facilities. Research output is substantial: principal investigators report individual publication counts of 70–250+ papers, and the institute holds a portfolio of filed patent applications in medical devices and antimicrobials plus additional granted patents in allergy/immunology and pharmaceutical collaborations. Certifications include HRS4R, UNE 166002, AENOR/ISO quality standards, GCP compliance, and ISO 27001.

The business model is grant- and contract-funded rather than commercially productized. Revenue is derived from national competitive grants (ISCIII/FIS), regional government funding (Junta de Andalucía), European Commission framework programmes (Horizon 2020/Horizon Europe projects such as iGAME, SAFE-T, and TransBioLine), pharmaceutical-sponsored clinical trial contracts (GSK, Gilead, Bristol-Myers Squibb, IQVIA), and technology transfer activities. The institute serves four principal constituencies: biomedical and clinical researchers, university researchers and students, regional healthcare providers (Hospital Regional Universitario de Málaga, Hospital Universitario Virgen de la Victoria, Hospital Civil), and the pharmaceutical industry. The management entity is FIMABIS (Fundación para la Investigación de Málaga en Biomedicina y Salud), which handles funding, contracts, HR, and institutional operations.

IBIMA firmographics

Firmographics

Name: IBIMA
Legal name: Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND)
Website: https://ibima.eu
Company type: Private
Founded year: 2010
Operating status: Operating
Headcount range: 51–100 employees
Short description: IBIMA is a public non-profit biomedical research institute in Málaga, Spain, accredited by ISCIII, conducting translational research across eight disease areas and nanomedicine, funded by public grants and pharmaceutical clinical trial partnerships.
Ownership category
akta.pro rank

IBIMA industry classification

Industry

Product category: Biomedical Research Services
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
SIC: Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry: PRIMARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
Healthcare & Life Sciences/Specialist Medical Practice/Gastroenterology & Hepatology

Keywords

Biomedical research services
Nanomedicine platform
Clinical research trials
Translational research
Rare diseases research

Where IBIMA is headquartered

Location

Headquarters

HQ city: Málaga
HQ country: Spain
HQ region: Europe

Offices1 record

Markets served

IBIMA business model

Business model

GTM type: B2B
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels3 records

Marketing channels6 records

IBIMA product offering

Product offering

Core offering

IBIMA Plataforma BIONAND is a non-profit biomedical research institute that conducts multidisciplinary translational research across eight areas (cardiovascular/obesity/diabetes, oncology-hematology, neurosciences, autoimmune/infectious diseases, rare diseases, nanodiagnostics, and advanced nanosystems therapies) and provides specialized research support services through ICTS-accredited platforms including Nanoimaging, Biobank, Genomics, Proteomics, Metabolomics, Bioinformatics, Cell Cultures, Histology, and GMP Cellular Manufacturing. The institute also manages clinical trials, technology transfer activities, and continuous training programs for healthcare and university researchers.

Product overview

IBIMA Plataforma BIONAND is a Health Research Institute (Instituto Sanitario de Investigación) created in July 2010 through an agreement between the Regional Ministry of Health of Andalusia and the University of Málaga. It operates as a multidisciplinary research center combining basic and clinical biomedical research with nanomedicine capabilities. The institute is structured around eight main research areas covering cardiovascular diseases, obesity and diabetes, oncology-hematology, neurosciences, autoimmune diseases, rare diseases (IBIMA-Rare), nanodiagnostics, and advanced nanosystems therapies (IBIMATech). Research support is provided through multiple specialized platforms including Nanoimaging, Biobank, Bioinformatics, Cell Cultures, Genomics, Proteomics, Metabolomics, Histology, and GMP-certified Cellular Manufacturing facilities. The institute also offers clinical research services, innovation and technology transfer programs, international mobility schemes, and continuous professional training through specialized courses and doctoral programs.

Differentiator

Problem solved

Functional benefit

Brands

IBIMA-Rare: Research area focused on rare diseases
IBIMATECH
IBIMA Plataforma BIONAND

Products and services

Nanoimaging Service (ICTS NANBIOSIS Node)
Biobank Service
Clinical Research Services
GMP Cellular Manufacturing Service
Multi-Omics Platform Services (Genomics, Proteomics, Metabolomics, Bioinformatics) Specialized omics platforms providing genomics sequencing, proteomics analysis, metabolomics profiling, and bioinformatics support for translational research projects in cardiovascular, oncology, autoimmune, and rare disease areas.
IBIMA-Rare (Rare Diseases Research Unit)
IBIMATech (Health Technology and Innovation Area)
Continuous Training Programs Educational offerings including clinical research diplomas, specialized biomedical courses, workshops, seminars, and doctoral programs for healthcare professionals and researchers.

Quantifiable outcome

One of more than 30 accredited health research institutes in Spain
+3 more outcomes

Companies that use IBIMA

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

IBIMA technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IBIMA partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and supporting.

Junta de Andalucía - Consejería de SaludcoreStrategic or Co-development Partner · 1 July 2010Founding institutional partner that established IBIMA in July 2010 through an agreement with the Regional Ministry of Health. Provides ongoing funding and institutional support for biomedical research activities.
Universidad de MálagacoreStrategic or Co-development Partner · 1 July 2010Founding academic partner in the July 2010 agreement. Provides university researchers, academic infrastructure, and joint research programs. Researchers from the university work alongside healthcare professionals in the institute.
Instituto de Salud Carlos IIIcoreStrategic or Co-development PartnerNational health research institute that accredited IBIMA as a Health Research Institute on January 15, 2015. Provides national research funding, FIS grants, and coordinates the network of accredited health research institutes in Spain.
FIMABIS (Fundación para la Investigación de Málaga en Biomedicina y Salud)coreStrategic or Co-development PartnerManagement body of IBIMA Plataforma BIONAND. Acts as the legal entity handling funding, contracts, HR management, and institutional operations for the research institute.
Málaga Techpark (Parque Tecnológico de Andalucía)coreOthersTechnology park location hosting IBIMA's main headquarters at Avenida Severo Ochoa. Provides research infrastructure and proximity to other technology and biotechnology companies.
CIBER (Biomedical Research Networking Centres)coreStrategic or Co-development PartnerIBIMA researchers participate in various CIBER networks including CIBERER (Rare Diseases), CIBEREHD (Hepatology), CIBER of Physiopathology of Obesity and Nutrition, and others, enabling national research collaboration.
European Clinical Research Infrastructure Network (ECRIN)majorStrategic or Co-development PartnerEuropean network supporting multinational clinical research. IBIMA participates through SCReN (Spanish Clinical Research Network) for international clinical trials.
SCReN (Spanish Clinical Research Network)majorStrategic or Co-development PartnerSpanish clinical research network of ISCIII that supports and coordinates clinical trials. IBIMA collaborates with SCReN for clinical trial design and execution.
NANBIOSIS ICTScoreStrategic or Co-development PartnerSingular Scientific and Technological Infrastructure network for nanomedicine. IBIMA's Nanoimaging Unit operates as an independent node of NANBIOSIS, providing access to specialized national infrastructure.
EURAXESS SpainsupportingOthersEuropean initiative supporting researcher mobility. IBIMA uses EURAXESS portal to attract international talent and provide information on residence permits, social security, and career development for foreign researchers.
Pharmaceutical companies (various)majorStrategic or Co-development PartnerIBIMA conducts clinical trials sponsored by pharmaceutical companies including GSK, Gilead, Bristol-Myers Squibb, IQVIA, and others. These partnerships provide funding for clinical research and access to novel therapeutics.

Scale indicators17 records

Recent moves9 records

Expansion highlights6 records

IBIMA competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

IBIMA compliance and trust

Trust signal

Compliance5 records

IBIMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IBIMA leadership team

Management profile

Number of profiles

Profiles1 record

IBIMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IBIMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBIMA

What does IBIMA do?

Is IBIMA a public or private company?

IBIMA is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was IBIMA founded?

IBIMA was founded in 2010. It employs 51 to 100 people.

Where is IBIMA based?

IBIMA is headquartered in Málaga, Spain, in the Europe region.

Does IBIMA have an API?

No public API is recorded for IBIMA.

What industry is IBIMA in?

IBIMA's product category is Biomedical Research Services. Its primary akta.pro industry code is HLAGANAE, Transcriptomics & Gene Expression Profiling Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 541714 and its SIC code is 8731.